Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  2012-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.metabol.2011.11.011PMID 22225957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

  2011cited by this paper
• Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.

  2011cited by this paper
• Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice.

  2010cited by this paper
• The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

  2010cited by this paper
• The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes

  2010cited by this paper
• Preventive Effects of Heregulin-&bgr;1 on Macrophage Foam Cell Formation and Atherosclerosis

  2009cited by this paper
• GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

  2009cited by this paper
• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

  2008cited by this paper
• Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice

  2008cited by this paper
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007cited by this paper
• DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.

  2007cited by this paper
• Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice

  2007cited by this paper
• Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.

  2005cited by this paper
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

  2004cited by this paper
• 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

  2003cited by this paper
• High-performance liquid chromatography of serum lipoproteins.

  1986cited by this paper

• The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease

  2024cites this paper
• Effect of physical exercise on metabolism in patients with atrial fibrillation

  2024cites this paper
• The antiatherosclerotic action of 1G244 - An inhibitor of dipeptidyl peptidases 8/9 - is mediated by the induction of macrophage death.

  2023cites this paper
• SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis

  2023cites this paper
• Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review.

  2023cites this paper
• Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art

  2022cites this paper
• Near-infrared probe for early diagnosis of diabetic complications-nephropathy and in vivo visualization fluorescence imaging research.

  2022cites this paper
• Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?

  2021cites this paper
• Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway

  2021cites this paper
• Novel Therapeutical Approaches to Managing Atherosclerotic Risk

  2021cites this paper
• GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

  2020cites this paper
• A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression

  2020cites this paper
• Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

  2020cites this paper
• Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice.

  2019cites this paper
• A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients

  2018cites this paper
• Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.

  2017cites this paper
• The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Reduces Aortic Damage from Hypercholesterolaemia in Apolipoprotein E-Deficient Mice

  2017cites this paper
• Exploring the effects of DPP‐4 inhibitors on the kidney from the bench to clinical trials

  2017cites this paper
• Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice

  2017cites this paper
• Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients

  2017cites this paper
• A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice.

  2016cites this paper
• Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in experimental animals

  2016cites this paper
• Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies

  2016cites this paper
• DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control

  2016cites this paper
• Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.

  2016cites this paper
• Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice.

  2016cites this paper
• Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice

  2015cites this paper
• Glucose-Dependent Insulinotropic Polypeptide (GIP) Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB

  2015cites this paper
• Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches

  2015cites this paper
• DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.

  2015cites this paper
• Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study.

  2015cites this paper
• Dipeptidyl Peptidase-4 Inhibitor Decreases Abdominal Aortic Aneurysm Formation through GLP-1-Dependent Monocytic Activity in Mice

  2015cites this paper
• The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis

  2015cites this paper
• Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients

  2015cites this paper
• The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice

  2015cites this paper
• Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.

  2015cites this paper
• Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study

  2015cites this paper
• Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB

  2015cites this paper
• A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis.

  2014cites this paper
• Potential cardioprotective action of GLP-1: from bench to bedside.

  2014cites this paper
• Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus.

  2014cites this paper
• Glucagon-like Peptide-1 Suppresses the Proliferation and Migration of Vascular Smooth Muscle Cells: Implications for Preventive Effects on Atherosclerosis

  2014cites this paper
• The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms

  2014cites this paper
• DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.

  2014cites this paper
• Incretin-based therapies, glucometabolic health and endovascular inflammation.

  2014cites this paper
• Evaluation the Effects of Sitagliptin on Atherosclerosis Progression in High Cholesterol- Fed Male Rabbits

  2014cites this paper
• The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study

  2014cites this paper
• GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways.

  2013cites this paper
• A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.

  2013influential citation
• Direct cardiovascular effects of glucagon like

  2013cites this paper
• Advances in metabolism.

  2013cites this paper
• Hypolipidemic and antiatherosclerotic potential of Pleurotus ostreatus, cultived by submerged fermentation in the high-fat diet fed rats

  2013cites this paper
• Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.

  2013cites this paper
• DPP-4 inhibitors repress foam cell formation by inhibiting scavenger receptors through protein kinase C pathway

  2013cites this paper
• Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

  2013cites this paper
• Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice

  2013cites this paper
• GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.

  2013cites this paper
• The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study.

  2013cites this paper
• Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases.

  2013cites this paper
• [Angioprotective properties of blood sugar lowering drugs from the group of inhibitors of dipeptidyl peptidase-4].

  2013cites this paper
• Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas

  2013cites this paper
• Direct cardiovascular effects of glucagon like peptide-1

  2013cites this paper
• Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis

  2013cites this paper
• Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice

  2012influential citation
• Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.

  2012cites this paper
• Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates

  2012cites this paper
• On- en off-targeteffecten van dipeptidyl peptidase-4-remmers

  2012cites this paper
• Glucose-Dependent Insulinotropic Polypeptide

  2011cites this paper